Related Experiment Videos
Myoblast transfer in heart failure.
1Department of Cardiovascular Surgery, Hôpital Bichat Claude Bernard, 46 rue Henri Huchard, Paris 75018, France. ccv-bloc.sec3@bch.ap-hop-paris.fr
The Surgical Clinics of North America
|April 1, 2004
Summary
Skeletal myoblast transfer shows promise for advanced left-ventricular ischemic dysfunction. Large, randomized trials adhering to drug trial guidelines are now essential to confirm its effectiveness and patient impact.
Area of Science:
- Regenerative Medicine
- Cardiology
- Cell Therapy
Background:
- Advanced left-ventricular ischemic dysfunction significantly impacts patient outcomes.
- Skeletal myoblast transfer is an emerging therapeutic option for cardiac repair.
Purpose of the Study:
- To determine the necessity of large-scale, randomized trials for skeletal myoblast transfer.
- To establish methodological standards for evaluating this cell therapy in cardiac patients.
Main Methods:
- Initiating a large randomized trial with 300 patients.
- Applying stringent methodologic guidelines, similar to those used in drug trials.
Main Results:
- The current stage of myoblast transfer necessitates rigorous clinical evaluation.
- Standardized trial design is crucial for reliable efficacy assessment.
Conclusions:
- Large, randomized trials are mandatory to validate skeletal myoblast transfer efficacy.
- Adherence to strict methodological guidelines ensures accurate assessment of patient outcomes in advanced left-ventricular ischemic dysfunction.